Innovative companies from the biotech sector will continue to be on the radars of investors, and one of the companies worth tracking at this point is CytoDyn Inc. (OTC: CYDY). Yesterday, the leronlimab developer was in the news after it made a major new announcement with regards to promising outcomes from a group of patients treated with its flagship product.
Promising Outcomes
In the news release yesterday, the company announced that its product, leronlimab, had been used to treat a cohort of patients suffering from mTNBC (metastatic triple negative breast cancer), and the survival outcomes had proven to be encouraging. The company noted that even though the prognosis for the ailment is almost always poor, the observed survival rates 12, 24, and 36 months since the beginning of treatment with leronlimab compared favorably with treatment outcomes with the therapies that are presently approved for treating mTNBC.
Further Details
The company went on to note in its news release that everyone at CytoDyn was encouraged by the survival data that had been recorded over the longer-term periods. The data could potentially lead to pathbreaking developments for patients suffering from the disease, the company observed yesterday.
What is the management saying?
“We are encouraged by the longer-term survival data to pursue this potentially paradigm-shifting therapeutic pathway for patients suffering from metastatic triple-negative breast cancer,” said Richard Pestell, MD, PhD, AO, the company’s lead consultant in preclinical and clinical oncology. “As a cancer therapeutic, leronlimab was well tolerated with remarkably infrequent treatment-related adverse events. These promising results suggest further studies with leronlimab are warranted to expand oncology treatment options and improve patient care.”
Traders Notes
| +/- EMA(20) | 0.25 (+20.04%) |
| +/- SMA(50) | 0.18 (+66.72%) |
| +/- SMA(200) | 0.15 (+100.07%) |
| 5-Day Perf. | +26.68% |
| 1-Month Perf. | +34.57% |
| 3-Month Perf. | +155.62% |
| 6-Month Perf. | +137.23% |
| YTD Perf. | +173.56% |
| 1-Year Perf. | +79.59% |
| RSI(14) | 67.11 |
| ATR(14) | 0.05 |
| ADX(14) | 51.03 |
| Beta (5Y) | 0.42 |
